Dana Button1, Ryan Cook2, Caroline King3, Tong Thi Khuyen4, Lynn Kunkel2, Gavin Bart5, Dinh Thanh Thuy4, Diep Bich Nguyen4, Christopher K Blazes6, Le Minh Giang4, P Todd Korthuis2. 1. MD/MCR Program, School of Medicine, Oregon Health & Science University, Portland, OR, USA. Electronic address: buttond@ohsu.edu. 2. Department of Medicine, Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, USA. 3. MD/PhD Program, School of Medicine, Oregon Health & Science University, Portland, OR, USA. 4. Hanoi Medical University, Hanoi, Vietnam. 5. Hennepin Healthcare, Minneapolis, MN, USA. 6. Department of Psychiatry, Oregon Health & Science University, Portland, OR, USA.
Abstract
BACKGROUND: In Vietnam, access to medications for opioid use disorder (MOUD) for people living with HIV has rapidly expanded, but MOUD use over time remains low. We sought to assess factors associated with days of MOUD treatment exposure. METHODS: From 2015 to 2019, patients with OUD in six Northern Vietnamese HIV clinics were randomized to receive HIV clinic-based buprenorphine (BUP/NX) or referral for methadone maintenance therapy (MMT) and followed for 12 months. All MOUD doses were directly observed and abstracted from dosing logs. The primary outcome was days of MOUD treatment exposure (buprenorphine or methadone) received over 12 months. Negative binomial regression modelled associations with days of MOUD exposure. RESULTS: Of 281 participants, 264 (94%) were eligible for analysis. Participants were primarily male (97%), unmarried (61%), employed (54%), and previously arrested (83%). Participants had a mean 187 (SD 150) days of MOUD exposure with 134 (51%) having at least 180 days, and 35 (13.2%) having at least 360 days of MOUD exposure. Age (IRR 1.26, 95% CI 1.02-1.55), income (IRR 0.96, 95% CI 0.93-1.001), and methadone (IRR 1.88, 95% CI 1.51-2.42) were associated with MOUD exposure in multivariate models. Multivariate models predicted 127 (95% CL 109-147) days of MOUD exposure for HIV clinic based-buprenorphine vs 243 (95% CL 205-288) for MMT. CONCLUSION: MOUD treatment exposure was suboptimal among patients with HIV and OUD in Northern Vietnam and was influenced by several factors. Interventions to support populations at risk of lower MOUD exposure as well programs administering MOUD should be considered in countries seeking to expand access to MOUD.
BACKGROUND: In Vietnam, access to medications for opioid use disorder (MOUD) for people living with HIV has rapidly expanded, but MOUD use over time remains low. We sought to assess factors associated with days of MOUD treatment exposure. METHODS: From 2015 to 2019, patients with OUD in six Northern Vietnamese HIV clinics were randomized to receive HIV clinic-based buprenorphine (BUP/NX) or referral for methadone maintenance therapy (MMT) and followed for 12 months. All MOUD doses were directly observed and abstracted from dosing logs. The primary outcome was days of MOUD treatment exposure (buprenorphine or methadone) received over 12 months. Negative binomial regression modelled associations with days of MOUD exposure. RESULTS: Of 281 participants, 264 (94%) were eligible for analysis. Participants were primarily male (97%), unmarried (61%), employed (54%), and previously arrested (83%). Participants had a mean 187 (SD 150) days of MOUD exposure with 134 (51%) having at least 180 days, and 35 (13.2%) having at least 360 days of MOUD exposure. Age (IRR 1.26, 95% CI 1.02-1.55), income (IRR 0.96, 95% CI 0.93-1.001), and methadone (IRR 1.88, 95% CI 1.51-2.42) were associated with MOUD exposure in multivariate models. Multivariate models predicted 127 (95% CL 109-147) days of MOUD exposure for HIV clinic based-buprenorphine vs 243 (95% CL 205-288) for MMT. CONCLUSION: MOUD treatment exposure was suboptimal among patients with HIV and OUD in Northern Vietnam and was influenced by several factors. Interventions to support populations at risk of lower MOUD exposure as well programs administering MOUD should be considered in countries seeking to expand access to MOUD.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Amy J Kennedy; Charles B Wessel; Rebecca Levine; Kendall Downer; Megan Raymond; Deborah Osakue; Iman Hassan; Jessica S Merlin; Jane M Liebschutz Journal: J Gen Intern Med Date: 2021-01-19 Impact factor: 5.128
Authors: E Jennifer Edelman; Yu Li; Declan Barry; Jennifer Brennan Braden; Stephen Crystal; Robert D Kerns; Julie R Gaither; Kirsha S Gordon; Ajay Manhapra; Jessica S Merlin; Brent A Moore; Benjamin J Oldfield; Lesley S Park; Christopher T Rentsch; Melissa Skanderson; Emily C Williams; Amy C Justice; Janet P Tate; William C Becker; Brandon D L Marshall Journal: J Acquir Immune Defic Syndr Date: 2020-05-01 Impact factor: 3.771